Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Sold by Pura Vida Investments LLC

Pura Vida Investments LLC lowered its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 41.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 113,041 shares of the company’s stock after selling 78,898 shares during the period. Establishment Labs comprises about 16.5% of Pura Vida Investments LLC’s portfolio, making the stock its biggest holding. Pura Vida Investments LLC owned about 0.40% of Establishment Labs worth $5,208,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Barclays PLC boosted its holdings in Establishment Labs by 9,643.3% in the third quarter. Barclays PLC now owns 31,471 shares of the company’s stock valued at $1,362,000 after acquiring an additional 31,148 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Establishment Labs by 89.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,351 shares of the company’s stock worth $1,789,000 after buying an additional 19,531 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Establishment Labs in the fourth quarter valued at $12,898,000. Point72 Asset Management L.P. raised its stake in Establishment Labs by 210.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 49,400 shares of the company’s stock worth $2,138,000 after buying an additional 33,507 shares during the period. Finally, Bamco Inc. NY grew its position in Establishment Labs by 13.6% in the 3rd quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock valued at $21,176,000 after purchasing an additional 58,611 shares during the period. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Stock Performance

Establishment Labs stock opened at $40.43 on Friday. Establishment Labs Holdings Inc. has a twelve month low of $28.16 and a twelve month high of $60.12. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The firm has a fifty day simple moving average of $36.36 and a two-hundred day simple moving average of $40.81. The company has a market capitalization of $1.17 billion, a PE ratio of -15.67 and a beta of 0.95.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm had revenue of $44.51 million during the quarter, compared to analysts’ expectations of $44.45 million. Research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “overweight” rating and issued a $52.00 target price on shares of Establishment Labs in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.40.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.